Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short-term Investments (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Short-term Investments data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 15.51% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 15.51%, while the annual FY2025 figure was $1.5 million, 15.51% up from the prior year.
  • Short-term Investments reached $1.5 million in Q4 2025 per APLS's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $458.2 million in Q1 2021 and bottomed at $1.1 million in Q2 2023.
  • Average Short-term Investments over 5 years is $40.7 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: soared 100.26% in 2021, then tumbled 99.62% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $1.6 million in 2021, then decreased by 18.55% to $1.3 million in 2022, then dropped by 12.49% to $1.1 million in 2023, then grew by 18.67% to $1.3 million in 2024, then rose by 15.51% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $1.5 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.